The immunology behind this combined approach, which yielded synergistic antitumor effects, is very interesting in that checkpoint inhibitors, such as Yervoy, Keytruda, and Opdivo act to stimulate the adaptive part of the immune system, whereas Coley’s Vaccine activates the innate immune system.
Las Vegas, NV (PRWEB) September 16, 2017
Preclinical and clinical data support efficacy of novel approach to cancer immunotherapy developed by CHIPSA hospital.
CHIPSA Hospital, dedicated to the accelerated development of nontoxic cancer immunotherapies announced today filing of a patent application covering the combination of FDA approved antibodies known as “checkpoint inhibitors” together with Coley Vaccine, a stimulatory of innate immunity. CHIPSA is the only licensed hospital facility (under doctor supervision) treating with the Coley’s Vaccine in North America. The patent was based on animal data using the established B16 melanoma mouse model, as well as patient cases.
“CHIPSA is one of the oldest hospitals to be using Coley’s Vaccine therapy. Our experiences and published literature suggests that Coley’s Vaccine is one of the most potent activators of the innate immune system,. Given that cellular components of the innate immune system such as macrophage and dendritic cells play a fundamental role in the visibility of cancer to the immune system, we believe that activating these cells with Coley’s will increase responsiveness to checkpoint inhibitors. This belief is supported by animal experiments and pilot human studies.” Said Edward Clay, Former CEO of CHIPSA Hospital and now Chief Executive of United Cancer Centers, as well as coinventor of the patent.
Currently, only about 20% of patients with advanced cancer respond to checkpoint inhibitors. Data generated by CHIPSA collaborators and published data suggests that stimulating the innate immune system makes tumors more visible to the adaptive immune system, thus potentially increasing the number of patients responding to checkpoint inhibitors.
“The immunology behind this combined approach, which yielded synergistic antitumor effects, is very interesting in that checkpoint inhibitors, such as Yervoy, Keytruda, and Opdivo act to stimulate the adaptive part of the immune system, whereas Coley’s Vaccine activates the innate arm of the immune system. Classical immunology teaches us that the innate and adaptive arms of the immune system work in synergy. By concurrent activation of both of these arms of the immune system, we believe we are driving the immune system into a state of overdrive, thus overcoming tumor associated immune suppression and increasing probability of remission.” Said Dr. Thomas Ichim, coinventor of the patent.
“I am proud to have led the clinical implementation of combining Coley’s Vaccine, which has been used for more than 100 years, with cutting edge immunological treatments like checkpoint inhibitors. The filing of today’s patent, is testimony to how here at CHIPSA we go the extra mile to offer the most advanced medicines to our patients.” Said Dr. Stephen Iacaboni, an Award Winning former MD Anderson Oncologist, who along with the other doctors at CHIPSA, performed the first combination therapies of Coley’s Vaccine with Checkpoint Inhibitors.
CHIPSA (Centro Hospitalario Internacional del Pacifico, S.A.) is a full service hospital caring for families with sick and injured within the ocean-front suburb of Playas de Tijuana. Since inception in 1979, CHIPSA Gerson integrative medical practice has become world renown and has been long identified as the home of Mexico’ Center for Integrative Medicine and Research. Our founding legacy, Gerson Therapy, represents the original medical practice of immuno-nutrition therapy developed by Max B. Gerson, M.D. (founder of immune-nutrition) known for his many contributions to address chronic, degenerative and infectious disease, as well as the documentation and remission of cancer.
 Jessy T. Immunity over inability: The spontaneous regression of cancer. J Nat Sci Biol Med. 2011 Jan;2(1):43-9. [2 Maletzki et al. Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin. Clin Dev Immunol. 2012;2012:230625 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502841/